Evidence map›Paper›PMID 32316671›Full record

ArticleCancers2020

Erbb4 Is Required for Cerebellar Developmentand Malignant Phenotype of Medulloblastoma.

Juncal Aldaregia, Peio Errarte, Ane Olazagoitia-Garmendia, Marian Gimeno, Jose Javier Uriz, Timothy R Gershon, Idoia Garcia, Ander Matheu

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Juncal AldaregiaCellular Oncology group, Biodonostia Health Research Institute, Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
Peio ErrarteCellular Oncology group, Biodonostia Health Research Institute, Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
Ane Olazagoitia-GarmendiaCellular Oncology group, Biodonostia Health Research Institute, Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
Marian GimenoCellular Oncology group, Biodonostia Health Research Institute, Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
Jose Javier UrizDonostia University Hospital, 20014 San Sebastian, Spain.
Timothy R GershonDepartment of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC 27516, USA.
Idoia GarciaCellular Oncology group, Biodonostia Health Research Institute, Dr. Beguiristain s/n, 20014 San Sebastian, Spain.
Ander MatheuCellular Oncology group, Biodonostia Health Research Institute, Dr. Beguiristain s/n, 20014 San Sebastian, Spain.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Instituto de Salud Carlos III PI16/01730NCI NIH HHS P30 CA016086
6 · The paper itself

Abstract

Medulloblastoma is the most common and malignant pediatric brain tumor in childhood. It originates from dysregulation of cerebellar development, due to an excessive proliferation of cerebellar granule neuron precursor cells (CGNPs). The underlying molecular mechanisms, except for the role of SHH and WNT pathways, remain largely unknown. ERBB4 is a tyrosine kinase receptor whose activity in cancer is tissue dependent. In this study, we characterized the role of ERBB4 during cerebellum development and medulloblastoma progression paying particular interests to its role in CGNPs and medulloblastoma stem cells (MBSCs). Our results show that ERBB4 is expressed in the CGNPs during cerebellum development where it plays a critical role in migration, apoptosis and differentiation. Similarly, it is enriched in the population of MBSCs, where also controls those critical processes, as well as self-renewal and tumor initiation for medulloblastoma progression. These results are translated to clinical samples where high levels of ERBB4 correlate with poor outcome in Group 4 and all medulloblastomas groups. Transcriptomic analysis identified critical processes and pathways altered in cells with knock-down of

Indexed as

cellular plasticitycerebellum developmentERBB4medulloblastoma

Identifiers

PMID32316671
PMCPMC7226104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.